The mission of the UCSF-GIVI CFAR Virology Core is to provide innovative and high quality virology to enhance the multidisciplinary research mission of the Center. To fulfill its goals, the Virology Core actively engages CFAR investigators, other core laboratories, NIH-sponsored clinical trial networks and industry partners by: 1) delivering a broad range of laboratory services and molecular diagnostics to support studies of HIV-infected subjects;2) developing and implementing cutting edge technologies to allow investigators to extend and explore new experimental areas;3) facilitating technology transfer through collaborations with industry and laboratories including those in resource-limited settings;4) providing support for high priority CFAR initiatives including projects focused on viral latency and viral eradication, pre-exposure chemoprophylaxis and vaccine trials for prevention of HIV transmission, HIV infection in women and in aging subjects and the causes and consequences of antiviral drug resistance;5) taking the lead on creating synergy between CFAR cores to provide improved service and enhanced efficiency;and 6) mentoring and training of staff, trainees and scientists, especially those inexperienced in virology, with the aim of enhancing their research programs and career development. The Virology Core has a proven track record. During the last 4 years, this Core played a key role in 129 research studies and clinical trials supporting $33 million in NIH-sponsored projects at UCSF and affiliated organizations, contributing data to 66 manuscripts and presenting its findings at high-profile international research conferences. The Core has also provided laboratory support for 45 independent investigators of which nearly half are at an early career stage. The Core leadership has also actively mentored and trained 27 students and fellows, many of whom now lead active research programs. Further, the Core has provided clinical drug resistance genotyping to hundreds of healthcare providers under CLIA conditions, and actively consulted with providers in interpreting these test results. Finally, the core has provided 24 new assays and services, many of which represent state-of-the-art diagnostics to measure complex viral populations that fills a key unmet research need. Going forward, the Virology Core will continue to tailor its portfolio of services to meet the new challenges emerging in HIV research that are identified as a part of the UCSF-GIVI CFAR strategic planning process. Increased emphasis on international work will also occur.
The UCSF-GIVI CFAR Virology Core is committed to supporting multidisciplinary research focused on addressing critical questions in HIV/AIDS biology, treatment, and prevention. This approach has led to breakthrough discoveries changing patient care and providing new approaches for curbing HIV infection in the United States and at international sites. The Virology Core remains fully committed to training and supporting the work of the next generation investigators who join in our mission to end the HIV epidemic.
|Mmeje, Okeoma; van der Poel, Sheryl; Workneh, Meklit et al. (2015) Achieving pregnancy safely: perspectives on timed vaginal insemination among HIV-serodiscordant couples and health-care providers in Kisumu, Kenya. AIDS Care 27:6-Oct|
|Edwards, Jessie K; Cole, Stephen R; Adimora, Adaora et al. (2015) Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapy. J Acquir Immune Defic Syndr 68:241-4|
|Chan, Brian T; Weiser, Sheri D; Boum, Yap et al. (2015) Persistent HIV-related stigma in rural Uganda during a period of increasing HIV incidence despite treatment expansion. AIDS 29:83-90|
|Chan, Brian T; Weiser, Sheri D; Boum, Yap et al. (2015) Declining prevalence of probable depression among patients presenting for antiretroviral therapy in rural Uganda: the role of early treatment initiation. AIDS Behav 19:19-26|
|Psaros, Christina; Haberer, Jessica E; Boum 2nd, Yap et al. (2015) The factor structure and presentation of depression among HIV-positive adults in Uganda. AIDS Behav 19:27-33|
|Jagannathan, Prasanna; Eccles-James, Ijeoma; Bowen, Katherine et al. (2014) IFN?/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children. PLoS Pathog 10:e1003864|
|Dworkin, Shari L; Lu, Tiffany; Grabe, Shelly et al. (2014) What community-level strategies are needed to secure women's property rights in Western Kenya? Laying the groundwork for a future structural HIV prevention intervention. AIDS Care 26:754-7|
|Liu, Albert Y; Yang, Qiyun; Huang, Yong et al. (2014) Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One 9:e83736|
|Martinez, Priscilla; Tsai, Alexander C; Muzoora, Conrad et al. (2014) Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans. J Acquir Immune Defic Syndr 65:456-62|
|Rebeiro, Peter F; Horberg, Michael A; Gange, Stephen J et al. (2014) Strong agreement of nationally recommended retention measures from the Institute of Medicine and Department of Health and Human Services. PLoS One 9:e111772|
Showing the most recent 10 out of 355 publications